KIWI Platform
Alzheimer's Disease
Pre-clinicalActive
Key Facts
About ni2o
ni2o is a private, pre-revenue biotech startup founded in 2018, aiming to revolutionize the treatment of neurodegenerative diseases through an integrated AI and neuromodulation platform. The company's three-pillar approach includes an AI software for early detection (4cyte AI), a wearable EEG headcap for monitoring (tKIWI), and a micro-implant for therapy (KIWI Micro-Implant). While ambitious and technologically novel, the company is in a pre-clinical or early development stage, facing significant technical, regulatory, and commercial hurdles inherent to the neurotech space. Its success hinges on validating its platform and translating its vision into approved medical devices and therapies.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |